{"groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM), received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^7 autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells on Day 0.","id":"FG000","title":"Dose Escalation: 3 x 10^7 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"FG001","title":"Dose Escalation: 1 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"FG002","title":"Dose Escalation: 3 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^9 autologous anti-BCMA CAR T cells on Day 0.","id":"FG003","title":"Dose Escalation: 1 x 10^9 KITE-585"},{"description":"RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \\[Grade 2 chronic kidney disease\\]) received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 24 mg/m\\^2/day IV infusion for 3 days followed by single infusion of KITE-585 at a tolerable dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"FG004","title":"Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"}],"type":"Enrolled But Never Treated"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"Informed Consent Withdraw"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Withdrawal of Consent From Further Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"21 participants were screened.","recruitmentDetails":"Participants were enrolled at study sites in the United States."}